Interactions of a herbal combination that inhibits growth of prostate cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 5, 2004, Pages 384-390

  Chung, Vinh Q ^a   Tattersall, Martin ^b   Cheung, H T A ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Chinese herbal medicines; Isobologram; PC SPES; Prostate cancer; Synergy

Indexed keywords

DENDRANTHEMA MORIFOLIUM EXTRACT; GANODERMA LUCIDUM EXTRACT; GLYCYRRHIZA URALENSIS EXTRACT; HERBACEOUS AGENT; ISATIS INDIGOTA EXTRACT; PANAX NOTOGINSENG EXTRACT; PC SPES; RABDOSIA RUBESCENS EXTRACT; SABAL EXTRACT; SCUTELLARIA BAICALENSIS EXTRACT; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CYTOTOXICITY; DENDRANTHEMA MORIFOLIUM; DRUG ANTAGONISM; DRUG ISOLATION; DRUG POTENTIATION; EVALUATION; GANODERMA LUCIDUM; GINSENG; GLYCYRRHIZA; HUMAN; HUMAN CELL; ISATIS; MEDICINAL PLANT; PRIORITY JOURNAL; PROSTATE CANCER; RABDOSIA; SABAL; SCUTELLARIA BAICALENSIS;

CELL DIVISION; CELL LINE, TUMOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 2142646453     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0746-1     Document Type: Article

References (27)

1. Bayne CW, Donnelly F, Ross M, Habib FK (1999) Serenoa repens (Permixon): a 5α-reductase types I and II inhibitor - new evidence in a coculture model of BPH. Prostate 40:232-241
2. Butenko IG, Gladtchenko SV, Galushko SV (1993) Anti-inflammatory properties and inhibition of leukotriene C4 biosynthesis in vitro by flavonoid baicalein from Scutellaria baicalensis Georgy roots. Agents Actions 39:C49-51
3. Chen S, Wang X (1997) Herbal composition for treating prostate carcinoma. US Patent no. 5,665,393. http://patft.uspto.gov
4. Darzynkiewicz Z, Traganos F, Wu JM, Chen S (2000) Chinese herbal mixture PC SPES in treatment of prostate cancer. Int J Oncol 17:729-736
5. de la Taille A, Hayek OR, Buttyan R, Bagiella E, Burchardt M, Katz AE (1999) Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int 84:845-850
6. de la Taille A, Buttyan R, Hayek O, Bagiella E, Shabsigh A, Burchardt M, Burchardt T, Chopin DK, Katz AE (2000) Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 164:1229-1234
7. Deckers CLP, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos PN, Renier WO, Van Rijn CM (2000) Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41:1364-1374
8. Food and Drug Administration. MedWatch. The FDA Safety Information and Adverse Event Reporting Program. 2002 Safety Information Summaries, http://www.fda.gov/medwatch/ SAFETY/2002/safety02.htm#spes
9. Geliebter J, Mittelman A, Tiwari RK (2001) PC-SPES and prostate cancer. J Nutr 131:164S-166S
10. Gessner PK (1995) Isobolographic analysis of interactions: an update on applications and utility. Toxicology 105:161-179
11. Haddock MG, Ames MM, Bonner J (1995) Assessing the interaction of irradiation with etoposide or idarubicin. Mayo Clin Proc 70:1053-1060
12. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16-23
13. Kim J, Amorino GP, Pyo H, Cao Q, Price JO, Choy H (2001) The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int J Radiat Oncol Biol Phys 51:525-534
14. Kim KC, Kim IG (1999) Ganoderma lucidum extract protects DNA from strand breakage caused by hydroxyl radical and UV irradiation. Int J Mol Med 4:273-277
15. Konoshima T, Takasaki M, Tokuda H (1999) Anti-carcinogenic activity of the roots of Panax notoginseng. II. Biol Pharm Bull 22:1150-1152
16. Lee JM, Kwon H, Jeong H, Lee JW, Lee SY, Back SJ, Surh YJ (2001) Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytother Res 15:245-249
17. Oh WK, George DJ, Hackmann K, Manola J, Kantoff PW (2001) Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 57:122-126
18. Pfeifer BL, Pirani JF, Hamann SR, Klippel KF (2000) PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 85:481-485
19. Qin GW, Xu RS (1998) Recent advances in bioactive natural products from Chinese medicinal plants. Med Res Rev 18:375-382
20. Roks G, Deckers CLP, van Egmond J, Meinardi H, van Rijn CM (1999) Effects of monotherapy and poly therapy with antiepileptic drugs: an animal study. J Pharmacol Exp Ther 288:472-477
21. Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB, Dodgson SJ, Nortey SO, Maryanoff BE (1994) Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 35:450-460
22. Shibata S (2000) A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. J Pharm Soc Jpn 120:849-862
23. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM (2000) Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18:3595-3603
24. Sovak M, Seligson A, Konas M, et al (2002) PC-SPES in prostate cancer: an herbal mixture currently containing warfarin and previously diethylstilbestrol and indomethacin (abstract LB152). Annual Meeting of the American Association of Cancer Research, San Francisco
25. Tallarida RJ (2001) Drug synergism: its detection and applications. Perspect Pharmacol 298:865-872
26. Wang RL (1993) A report of 40 cases of esophageal carcinoma surviving for more than 5 years after treatment with drugs. Zhonghua Zhong Liu Za Zhi 15:300-302
27. Wilt TJ, Ishani A, Indulis R, MacDonald R (2000) Phytotherapy for benign prostatic hyperplasia. Public Health Nutr 3:459-472